Migraine Prevention and Allergic Rhinitis

Evidence Review

The Key Migraine RCT: Lipton et al. (2004)

The pivotal trial establishing butterbur as a Level A migraine preventive was a three-arm, parallel-group, randomized controlled trial conducted by Lipton and colleagues at multiple centers [1]. 245 patients meeting International Headache Society migraine criteria, aged 18–65 with 2–6 attacks per month over the preceding three months, were randomized to Petasites extract 75 mg twice daily, 50 mg twice daily, or matching placebo for four months.

The per-protocol analysis (n = 202) found:

• 75 mg twice-daily group: migraine attack frequency reduced by 48% (p = 0.0012 vs. placebo)
• 50 mg twice-daily group: 36% reduction (p = 0.127 vs. placebo — a trend but not statistically significant)
• Placebo group: 26% reduction (the typical placebo response in migraine trials)

The absolute superiority of the 75 mg dose over placebo was 22 percentage points, representing roughly one fewer migraine per month in a patient averaging 3–4 attacks per month at baseline. Responder rates — the proportion of patients achieving at least 50% reduction in attack frequency — were 68% with 75 mg, 56% with 50 mg, and 49% with placebo. The most common adverse events were burping (9.3% with butterbur vs. 3.7% with placebo) and nausea; no serious adverse events were attributed to the study drug.

This study used Petadolex, a PA-free standardized extract. It was classified as a Class I (highest quality) trial in the American Academy of Neurology evidence review and contributed to the Level A designation for butterbur in their 2012 guideline update.

AAN/AHS Level A Recommendation: Holland et al. (2012)

The American Academy of Neurology and American Headache Society jointly published an evidence-based guideline update reviewing complementary treatments for episodic migraine prevention [5]. After systematic review of the clinical trial evidence using their quality standards classification system, butterbur was the only natural product to receive a Level A recommendation — the same evidence tier as established pharmaceutical preventives such as topiramate, valproate, and propranolol.

The guideline stated that Petasites hybridus should be "offered to patients with migraine to reduce the frequency and severity of migraine attacks" (Level A, Class I evidence). This classification requires at least two high-quality, independently conducted RCTs showing efficacy — a standard that butterbur met through the Lipton 2004 trial and an earlier confirming study.

No other herbal treatment for migraine prevention meets this evidentiary bar. Feverfew, by comparison, received a Level B recommendation in the same guideline — one level below butterbur. Magnesium and riboflavin also received Level B recommendations.

Seasonal Allergic Rhinitis: Schapowal Trials (2002–2005)

Butterbur vs. cetirizine (2002): Schapowal and the Petasites Study Group conducted a randomized double-blind parallel group trial in 131 patients with seasonal allergic rhinitis, comparing Ze339 butterbur extract (one tablet four times daily) to cetirizine 10 mg once daily for two weeks [2]. Primary outcome was physician- and patient-rated overall symptom improvement on a validated scale.

Butterbur and cetirizine produced equivalent overall improvements in allergic symptom scores. Critically, patient-reported symptoms of drowsiness were significantly higher in the cetirizine group — a meaningful finding since first-generation antihistamine sedation is a primary reason patients discontinue allergy treatment. No serious adverse events were reported in either group. The equivalence to cetirizine without sedation established butterbur as a clinically relevant non-sedating option.

Dose-response study (2004): In a subsequent double-blind RCT in 186 patients randomized to Ze339 high-dose, low-dose, or placebo, both active doses significantly outperformed placebo on total nasal symptom scores, confirming dose-related efficacy and ruling out a non-specific effect [3].

Vs. fexofenadine (2005): A larger trial of 330 patients compared Ze339 to fexofenadine 180 mg and placebo over 2 weeks. Response rates by day 14 were 32% (butterbur) vs. 33% (fexofenadine) vs. 5% (placebo) [4]. No serious adverse events occurred in the butterbur group and no clinically significant changes in liver enzymes (ALT, AST, GGT) were observed — important safety confirmation at therapeutic doses.

Taken together, these three well-conducted trials provide consistent evidence that PA-free butterbur extract reduces allergic rhinitis symptoms comparably to second-generation antihistamines without inducing sedation. A systematic review of these trials (PMID 18219828) concluded butterbur was superior to placebo and equivalent to non-sedating antihistamines for intermittent allergic rhinitis.

Mechanism: 2022 Review by Borlak et al.

The most recent comprehensive review of butterbur's mechanism of action synthesized data from molecular pharmacology, receptor binding studies, and translational research [6]. The authors identified petasin and isopetasin as the therapeutically active compounds responsible for butterbur's effects in both migraine and allergies, with the following key findings:

• Petasins inhibit CGRP release from meningeal trigeminal afferents — directly targeting the primary neuropeptide driving migraine pain and vasodilation
• TRPA1 and TRPV1 desensitization by petasins reduces nociceptive input in trigeminal sensory neurons, an effect that persists after the acute dosing window and may account for the cumulative benefit seen with chronic preventive use
• Dual COX/LOX inhibition provides anti-inflammatory action relevant to both migraine and allergic inflammation, with leukotriene suppression particularly important for nasal congestion in allergic rhinitis (an effect antihistamines cannot address)
• The review confirmed that PA-free Petadolex at clinical doses did not produce hepatotoxicity in any of the controlled studies reviewed, though it noted that contaminated commercial products remain a real risk

Strength of Evidence and Limitations

The evidence base for butterbur in migraine prevention is unusually strong for a botanical: two independent high-quality RCTs with consistent results, a Level A classification from the highest-tier neurology body, and a mechanistically coherent set of pharmacological targets now shared with approved pharmaceutical agents.

For allergic rhinitis, the evidence is also strong — multiple RCTs, comparator-controlled, with consistent findings across independent research groups.

Primary limitations: migraine trials are relatively short (4 months); long-term safety data beyond 16 weeks is limited compared to established pharmaceuticals; most allergy studies used Ze339, and results may not extrapolate to different extracts. The PA safety issue means that product quality matters enormously — a well-evidenced botanical whose efficacy depends entirely on a specific, certified preparation.

For patients seeking evidence-based options for migraine prevention or allergy symptom management, butterbur represents one of the strongest data packages in botanical medicine — provided the PA-free sourcing requirement is rigorously observed.